Barclays raised the firm’s price target on Regeneron to $935 from $925 and keeps an Overweight rating on the shares post the Q3 report. The firm says the year-end COPD data pulls forward a key catalyst, while the company’s backdrop remains encouraging.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on REGN:
- Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH
- Regeneron upgraded to Outperform from Market Perform at Raymond James
- Regeneron Reports Third Quarter 2023 Financial and Operating Results
- Regeneron reports Q3 adjusted EPS $11.59, consensus $10.77
- Notable companies reporting before tomorrow’s open